Charles Zhou
Stock Analyst at UBS
(1.33)
# 3,474
Out of 4,937 analysts
10
Total ratings
57.14%
Success rate
-6.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $160.92 | -15.49% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $12.02 | +33.11% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $10.96 | +36.86% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.54 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.48 | +3,683.78% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.54 | +2,896.74% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $4.21 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $160.92
Upside: -15.49%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $12.02
Upside: +33.11%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $10.96
Upside: +36.86%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.54
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.48
Upside: +3,683.78%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.54
Upside: +2,896.74%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.21
Upside: -